168 related articles for article (PubMed ID: 21036138)
1. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).
Wu J; Siddiqui J; Nihal M; Vonderheid EC; Wood GS
Arch Biochem Biophys; 2011 Apr; 508(2):185-91. PubMed ID: 21036138
[TBL] [Abstract][Full Text] [Related]
2. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
3. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
4. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
5. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
6. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression.
Sun WH; Pabon C; Alsayed Y; Huang PP; Jandeska S; Uddin S; Platanias LC; Rosen ST
Blood; 1998 Jan; 91(2):570-6. PubMed ID: 9427711
[TBL] [Abstract][Full Text] [Related]
8. BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.
Esmailzadeh S; Huang Y; Su MW; Zhou Y; Jiang X
Leukemia; 2015 Jun; 29(6):1402-13. PubMed ID: 25578476
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
[TBL] [Abstract][Full Text] [Related]
10. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma.
Wu J; Wood GS
Arch Dermatol; 2011 Apr; 147(4):443-9. PubMed ID: 21173302
[TBL] [Abstract][Full Text] [Related]
11. Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1-STAT1 pathway.
Liszewski W; Naym DG; Biskup E; Gniadecki R
Photodermatol Photoimmunol Photomed; 2017 May; 33(3):164-171. PubMed ID: 28196286
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.
Qin JZ; Zhang CL; Kamarashev J; Dummer R; Burg G; Döbbeling U
Blood; 2001 Nov; 98(9):2778-83. PubMed ID: 11675351
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis.
Mao X; Orchard G; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
J Invest Dermatol; 2006 Jun; 126(6):1388-95. PubMed ID: 16614728
[TBL] [Abstract][Full Text] [Related]
14. FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.
Zhong-Xing Z; Yuan-Yuan M; Hai Zhen M; Jian-Gang Z; Li-Feng Z
PLoS One; 2013; 8(8):e73700. PubMed ID: 24014103
[TBL] [Abstract][Full Text] [Related]
15. c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.
Wu J; Salva KA; Wood GS
J Invest Dermatol; 2015 Mar; 135(3):861-868. PubMed ID: 25140833
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal imbalances: a hallmark of tumour relapse in primary cutaneous CD30+ T-cell lymphoma.
Prochazkova M; Chevret E; Beylot-Barry M; Sobotka J; Vergier B; Delaunay M; Turmo M; Ferrer J; Kuglik P; Merlio JP
J Pathol; 2003 Nov; 201(3):421-9. PubMed ID: 14595754
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
18. The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.
Olszewska B; Gleń J; Zabłotna M; Nowicki RJ; Sokołowska-Wojdyło M
Arch Dermatol Res; 2021 Jan; 313(1):25-31. PubMed ID: 32270320
[TBL] [Abstract][Full Text] [Related]
19. New Genetic Markers of Skin T-Cell Lymphoma Treatment.
Vašků V; Fialová P; Vašků A
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540417
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies.
Migliazza A; Lombardi L; Rocchi M; Trecca D; Chang CC; Antonacci R; Fracchiolla NS; Ciana P; Maiolo AT; Neri A
Blood; 1994 Dec; 84(11):3850-60. PubMed ID: 7949142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
